Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir.

María FontechaMarta MonsalvoMiguel A Rodriguez-SagradoMaría J VivancosAna MorenoJosé Luis Casado

Published in: Infectious diseases (London, England) (2019)

Our results demonstrated the long-term efficacy and safety of an antiretroviral regimen based on dual therapy with lamivudine plus boosted darunavir in the clinical setting.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
human immunodeficiency virus
hiv positive
hiv aids
bone mineral density
stem cells
mesenchymal stem cells
hepatitis c virus
postmenopausal women
replacement therapy